title: Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.
abstract: OBJECTIVE
  To retrospectively investigate the safety and efficacy of weekly topotecan in heavily pretreated patients with ovarian cancer.
  
  
  METHODS
  Data were collected by retrospective review of patient records. Eligible patients had received > or =2 prior regimens for ovarian cancer before treatment with weekly topotecan. Efficacy was determined by measurable disease or CA 125 levels. Adverse event and growth factor support data were also collected.
  
  
  RESULTS
  Fifty patients (median age, 61 years) were evaluable for safety and received a total of 244 4-week cycles of therapy (median, 3; range, 1-21 cycles). Most patients (84%) had measurable disease, and 30% had performance status of > or =2. Patients had received two to six prior treatments for ovarian cancer. Median weekly dose per patient was topotecan 3.7 mg/m(2). Grade 4 hematologic toxicities (generally manageable) occurred in 4% of patients. One patient had febrile neutropenia. Grade 3/4 nonhematologic toxicities were fatigue in two (4%) patients. Forty-two patients were evaluable for response. Of 35 evaluable patients with measurable disease, 11 (31%) had a partial response (median duration, 3 months), and 15 (43%) patients had stable disease (median duration, 3.5 months). Of 41 evaluable patients with elevated CA 125 (median, 154 U/l; range, 47-7200 U/l), 11 (27%) had > or =50% decreases or normalization of CA 125 levels. Median time to progression in all patients with stable disease has not been reached (follow-up range, 1.5-17.3 months).
  
  
  CONCLUSIONS
  Weekly topotecan is active and well tolerated in heavily pretreated patients with relapsed ovarian cancer. Prospective studies of this regimen are warranted.
authors.affiliation: Division of Gynecologic Obstetrics, University of Alabama at Birmingham, Birmingham, AL 35249, USA.
authors.forename: Snehal M
authors.initials: SM
authors.lastname: Bhoola
authors.forename: Robert L
authors.initials: RL
authors.lastname: Coleman
authors.forename: Thomas
authors.initials: T
authors.lastname: Herzog
authors.forename: Robert
authors.initials: R
authors.lastname: Morris
authors.forename: Christopher
authors.initials: C
authors.lastname: Bryant
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Estes
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D016879:Salvage Therapy; D019772:Topotecan / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan